When Chemotherapy Is Used for Prostate Cancer

---

Prostate cancer is not treated with chemotherapy in the way many people imagine. For early-stage or locally advanced disease, chemotherapy plays no role.

Surgery, radiation, and hormone therapy are the primary treatments at those stages. Chemotherapy enters the picture in two specific situations — and only two.

The first is metastatic hormone-sensitive prostate cancer in men with high-volume disease.

Multiple large trials — including CHAARTED and STAMPEDE — demonstrated that adding six cycles of docetaxel upfront to hormone therapy significantly extends survival in men with a heavy metastatic burden at diagnosis.

The second is castration-resistant prostate cancer — CRPC — where the cancer has progressed despite hormone therapy. At this stage, chemotherapy with docetaxel is the standard first-line treatment. When docetaxel stops working, cabazitaxel is the second-line option.

Understanding exactly where you are in the disease trajectory — hormone-sensitive or castration-resistant, localised or metastatic — determines which treatments are relevant for you.

Docetaxel — the First-Line Chemo for Advanced Prostate Cancer

---

Docetaxel is the most widely used chemotherapy drug for advanced prostate cancer globally and it remains the standard first-line chemotherapy agent at every stage of the disease where chemo is indicated.

It belongs to a class of drugs called taxanes. It works by interfering with the cell's internal structure — specifically the microtubules that cells need to divide — and causing cancer cells to stop multiplying and die.

Docetaxel is given as an intravenous infusion over one to two hours, once every three weeks. The standard course for prostate cancer is six cycles — one infusion every three weeks for a total of eighteen weeks.

What happens during a docetaxel infusion?

You come to the day care unit of the hospital in the morning. A cannula is placed and pre-medications — dexamethasone steroid and antihistamines — are given to reduce the risk of an allergic reaction. The docetaxel infusion then runs over approximately one to two hours.

Most patients go home the same day. There is no hospital admission required for a routine docetaxel infusion at India's major cancer centres.

Blood tests — particularly a full blood count to check for neutropenia — are done before each cycle to confirm it is safe to proceed. If the neutrophil count is too low, the cycle is delayed until it recovers.

Side effects of docetaxel — what to honestly prepare for

Neutropenia. The most significant risk is a drop in white blood cells — neutrophils specifically — that increases infection risk in the week to ten days after each infusion.

Fever above 38°C during this period — febrile neutropenia — is a medical emergency requiring immediate hospital assessment and intravenous antibiotics.

Growth factor injections (G-CSF, such as filgrastim) are given after each cycle at most major Indian centres to reduce this risk.

Fatigue. Significant fatigue typically peaks in the first week after each infusion and gradually improves before the next cycle. Most men find cycles two and three the hardest and then adapt somewhat.

Peripheral neuropathy. Tingling or numbness in the fingers and toes is common and cumulative — it tends to worsen with more cycles. In most men it improves after chemotherapy ends, but it can be persistent.

Hair loss. Complete hair loss — including body hair — typically begins two to three weeks after the first infusion and reverses after treatment ends. Most men find this one of the most visibly confronting side effects even though it is temporary.

Nail changes. Nail discolouration and separation from the nail bed — onycholysis — affects a significant proportion of men on docetaxel. Wearing well-fitting gloves and cooling nail beds during infusions reduces this risk at many centres.

Fluid retention. Docetaxel causes fluid to accumulate in tissues — ankle swelling and weight gain are common. This is managed with the dexamethasone pre-medication, which also doubles as an anti-inflammatory.

Cabazitaxel — Second-Line Chemotherapy After Docetaxel

---

When prostate cancer progresses during or after docetaxel — shown by rising PSA or new lesions on imaging despite chemotherapy — the standard second-line option is cabazitaxel.

Cabazitaxel is also a taxane but it works in tumours that have developed resistance to docetaxel. The TROPIC trial showed it significantly extended survival in men with CRPC that had progressed on docetaxel.

It is given as a three-weekly intravenous infusion over one hour, also for six cycles as a standard course. The side effect profile is similar to docetaxel but with a higher rate of severe neutropenia — G-CSF support after every cycle is mandatory.

Cabazitaxel is available in India as both branded Jevtana and as a quality-assured Indian generic.

The generic version — from manufacturers including Intas, Sun Pharma, and Cipla — costs USD 800 to 2,000 per cycle in India, compared to USD 8,000 to 20,000 per cycle in the United States.

For men who have progressed on docetaxel and need second-line chemotherapy, the cost differential for a six-cycle course can exceed USD 100,000 compared to US pricing.

PARP Inhibitors — Targeted Therapy for BRCA-Mutated Disease

---

PARP inhibitors — olaparib (Lynparza) and rucaparib (Rubraca) — are targeted oral therapies that work specifically in prostate cancers carrying mutations in DNA repair genes, most commonly BRCA1 or BRCA2.

Approximately 15 to 20 percent of men with metastatic CRPC carry a BRCA mutation.

For these men, PARP inhibitors have shown remarkable response rates — the PROfound trial demonstrated significantly longer progression-free survival for olaparib versus standard hormonal therapy in BRCA1/2-mutated CRPC.

PARP inhibitors are daily oral tablets, not infusions. This makes them far more compatible with ongoing management from home — the drug is taken daily, PSA and blood tests are monitored every four to eight weeks, and the treating oncologist is consulted periodically.

Genetic testing — who should be tested before considering PARP inhibitors

Every man with metastatic prostate cancer should have tumour genetic testing — either from the original biopsy tissue or from a liquid biopsy blood test — to look for BRCA1, BRCA2, and ATM mutations.

This testing is available in India at all major cancer centres. At Medanta, Tata Memorial, and Apollo Delhi, next-generation sequencing panels can be run on stored biopsy tissue.

This means you may not need a repeat biopsy if tissue from a previous procedure is available.

The cost of comprehensive genomic profiling in India is USD 400 to 1,200 — compared to USD 3,000 to 8,000 in the United States for the same test panels.

If a BRCA2 mutation is found, olaparib becomes one of the most important treatment options available. Generic olaparib in India — available from Sun Pharma and other licensed manufacturers — costs approximately USD 300 to 800 per month.

Branded Lynparza costs USD 13,000 to 18,000 per month in the United States. The saving over twelve months of treatment exceeds USD 150,000.

Immunotherapy — Pembrolizumab and When It Works

---

The honest truth about immunotherapy in prostate cancer is that it works — but only in a specific minority of patients.

Prostate cancer is generally what immunologists call a "cold tumour" — meaning it does not generate a strong immune response and is not well infiltrated with the immune cells that checkpoint inhibitors activate.

Broad immunotherapy with checkpoint inhibitors has modest results in unselected prostate cancer populations.

But in a subgroup of men with specific tumour characteristics — mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status — pembrolizumab (Keytruda) produces striking and durable responses.

How mismatch repair testing works

MMR/MSI testing looks at whether the cancer's DNA repair machinery is defective. When it is — dMMR or MSI-H — the tumour accumulates many mutations and presents them on its surface in ways that the immune system can recognise and attack once checkpoint inhibition is applied.

Approximately 3 to 5 percent of metastatic prostate cancers are MSI-H. It is a small proportion — but for those men, pembrolizumab is FDA-approved regardless of tumour type, and responses can be dramatic and long-lasting.

MMR/MSI testing can be done on the same tumour tissue used for BRCA testing. At major Indian centres, this is included in standard comprehensive genomic profiling panels.

For any man with metastatic CRPC that has progressed on multiple treatments, knowing MMR and MSI status should be considered essential before moving to later-line options.

Pembrolizumab in India — availability and cost

Pembrolizumab (Keytruda) is available at all major Indian cancer centres — Medanta, Apollo, Tata Memorial, Fortis FMRI, and others. It is given as an intravenous infusion every three or six weeks.

In India, pembrolizumab costs approximately USD 1,500 to 3,500 per infusion — compared to USD 10,000 to 20,000 per infusion in the United States. For MSI-H prostate cancer where pembrolizumab is indicated, the cost difference over a year of treatment is substantial.

It is worth noting that pembrolizumab is not indicated for unselected prostate cancer and should not be used outside of a formal tumour board recommendation.

Its side effects — immune-related adverse events including pneumonitis, colitis, hepatitis, and endocrine toxicity — require experienced oncology management.

Lutetium PSMA Therapy — Radioligand Treatment in India

---

Lutetium-177 PSMA therapy — also called Lu-PSMA or radioligand therapy — is one of the most significant advances in advanced prostate cancer treatment of the past decade.

It works by attaching a radioactive molecule (lutetium-177) to a PSMA-targeting ligand that seeks out prostate cancer cells wherever they are in the body.

The lutetium then delivers targeted radiation directly to each cancer cell — a concept sometimes called "precision nuclear medicine."

The VISION trial — published in the New England Journal of Medicine — showed that Lu-PSMA significantly extended overall survival and progression-free survival in men with PSMA-positive metastatic CRPC who had already received both hormone therapy and chemotherapy.

Is Lu-PSMA available in India?

Yes. Lutetium-177 PSMA therapy is available at select nuclear medicine and oncology centres in India — including Tata Memorial Hospital Mumbai, Apollo Hospitals, and a small number of other specialist centres with the required cyclotron and nuclear medicine infrastructure.

Before Lu-PSMA can be given, a PSMA PET-CT scan must confirm that the patient's tumours express sufficient PSMA — the target protein the therapy attaches to. This scan is available across India at USD 500 to 900, compared to USD 3,000 to 6,000 in the United States.

Lu-PSMA is given as a series of four to six intravenous infusions spaced six weeks apart. Each infusion requires a brief inpatient admission — typically one to two nights — because the patient emits a small amount of radiation for 48 to 72 hours after the infusion.

The cost of each Lu-PSMA cycle in India is approximately USD 4,000 to 8,000 — compared to USD 40,000 to 70,000 per cycle in the United States. For a patient needing six cycles, the saving compared to US pricing can exceed USD 250,000.

Full Cost Comparison — India vs UK and USA

---

The cost differences for advanced prostate cancer treatments between India and Western markets are not modest discounts. They are transformative differences that determine whether treatment is financially possible at all for most international patients.

A man with metastatic CRPC who needs docetaxel followed by PARP inhibitor therapy in the United States faces drug costs exceeding USD 200,000 per year.

In India, the same treatment sequence costs USD 8,000 to 20,000 per year — including all infusion fees, monitoring, and consultation costs.

Treatment	India	USA	UK (private)
Docetaxel (per cycle)	USD 200–600	USD 3,000–8,000	GBP 2,000–5,000
Docetaxel 6-cycle course	USD 1,200–3,600	USD 18,000–48,000	GBP 12,000–30,000
Cabazitaxel (per cycle)	USD 800–2,000	USD 8,000–20,000	GBP 5,000–12,000
Olaparib / PARP inhibitor (per month)	USD 300–800	USD 13,000–18,000	GBP 7,000–12,000
Pembrolizumab (per infusion)	USD 1,500–3,500	USD 10,000–20,000	GBP 6,000–12,000
Lu-177 PSMA (per cycle)	USD 4,000–8,000	USD 40,000–70,000	GBP 25,000–45,000
Genomic profiling / BRCA + MSI testing	USD 400–1,200	USD 3,000–8,000	GBP 2,000–5,000
PSMA PET-CT scan	USD 500–900	USD 3,000–6,000	GBP 2,500–4,000

For infusion-based treatments like docetaxel and pembrolizumab, the most practical model for international patients is to come to India for the infusion cycles and return home between them.

Each docetaxel cycle requires one day at the hospital — the morning of the infusion. Blood tests are done the day before. For a three-weekly cycle, most patients are in India for four to five days per visit.

For oral agents like olaparib, the drug is prescribed and dispensed in India and carried home by the patient — exactly as with abiraterone and enzalutamide.

Read the full cost guide: Prostate cancer treatment cost in India — complete breakdown →

Planning Systemic Treatment in India — Practical Guide

---

Managing advanced prostate cancer treatment from abroad requires more co-ordination than a single surgical episode — but it is entirely practical and thousands of men do it.

The key is establishing the treatment plan clearly before the first visit, so that every subsequent trip to India is focused on the treatment itself rather than on repeat evaluations.

What to send before your first visit

Send your complete treatment history — every drug you have received, in what doses, and for how long. Include your most recent PSA, testosterone level, and imaging report. If you have had genomic testing, include those results. If you have not, India can do it.

GAF Healthcare reviews your full history and identifies the right oncologist and hospital for your specific situation — not the nearest hospital or the most marketed one.

The oncology consultation

The first visit involves a full oncology consultation — typically a half-day — where the medical oncologist reviews your history, examines you, and confirms or adjusts the proposed treatment plan.

Blood tests are taken. If chemotherapy is planned, a pre-chemotherapy baseline is established. If BRCA or MSI testing has not been done, it is arranged from either stored tissue or fresh biopsy.

Ideally, the first infusion happens on the second or third day of the first visit — so you are not making a separate trip just for a consultation.

Between cycles — monitoring from home

Between chemotherapy cycles, the most important monitoring step is a full blood count at day 10 to 14 after each infusion — when the white cell count is at its lowest.

This can be done at any local pathology lab and the result sent to your Indian oncologist by WhatsApp. GAF Healthcare provides a blood test schedule and a reference chart so your local lab knows exactly what to measure and what values should trigger an urgent call.

PSA is checked before each cycle. Imaging — usually a CT and bone scan, or PSMA PET-CT for more accurate assessment — is done after every two to three cycles to assess treatment response.

"The oncologist in Dubai told us the chemo would cost USD 6,000 a cycle and they needed to do six cycles. We did not have that money. My wife searched online and we found GAF Healthcare. The same drug — same name, same dose — was USD 350 per cycle at Medanta. We flew from Dubai for each cycle. We stayed three nights each time. After six cycles my PSA had dropped from 84 to 3. The oncologist back home said the response was excellent."

— Mr. H. R., 68, UAE · Docetaxel for metastatic prostate cancer · Medanta Gurgaon, 2024–25